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Abstract
Background: The purpose of this study is to review our experience with the use of IORT for patients with
advanced cervical metastasis.
Methods: Between August 1982 and July 2007, 231 patients underwent neck dissections as part of initial therapy
or as salvage treatment for advanced cervical node metastases resulting from head and neck malignancies. IORT
was administered as a single fraction to a dose of 15 Gy or 20 Gy in most pts. The majority was treated with 5
MeV electrons (112 pts, 50.5%).
Results: 1, 3, and 5 years overall survival (OS) after surgery + IORT was 58%, 34%, and 26%, respectively.
Recurrence-free survival (RFS) at 1, 3, and 5 years was 66%, 55%, and 49%, respectively. Disease recurrence was
documented in 83 (42.8%) pts. The majority of recurrences were regional (38 pts), as compared to local recurrence
in 20 pts and distant failures in 25 pts. There were no perioperative fatalities.
Conclusions: IORT results in effective local disease control at acceptable levels of toxicity. Our results support the
initiation of a phase III trial comparing outcomes for patients with cervical metastasis treated with or without IORT.
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Background
The management of advanced or recurrent cervical node
metastases poses a challenge for surgeons and radiation
oncologists. In general, primary tumor sites which are
drained by a dense lymphatic supply, such as the naso-
pharynx and hypopharynx, are more prone to cervical
spread compared to tissues with more limited lympha-
tics, such as the paranasal sinuses, middle ear, and true
vocal folds [1]. In addition to the primary site’s lympha-
tic supply, the risk of cervical node metastasis rises
directly with the size of the primary tumor and inversely
with its histologic differentiation [2].
Complete resection of cervical node metastases is not
always feasible due to tumor proximity to vital struc-
tures such as the carotid artery or to fixation to deep
tissues such as the prevertebral fascia. In addition, prior
surgery and radiation therapy can induce tissue fibrosis
and alter the anatomy sufficiently to result in recognized
or unknown gross or microscopic residual neck disease.
Intraoperative radiation therapy has been available to
select head and neck cancer patients presenting to our
group since the 1980s [3,4]. IORT has been offered to
those patients who have metastatic nodal disease recur-
rent or persistent after prior surgery and/or radiation
treatment or who have nodal disease at initial presenta-
tion which in the judgment of the surgeon has a signifi-
cant chance of having gross or residual microscopic
cancer persistent at the conclusion of the surgery. The
IORT is delivered to the tumor bed following surgical
extirpation. The method of radiation at the time of sur-
gery allows for effective shielding and retraction of criti-
cal structures such as the cervicofacial skin,
laryngopharynx, and mandible, while allowing for maxi-
mal exposure of the tumor bed to the radiation beam.
IORT offers several radiobiologic advantages including
decreased tumor repopulation and improved targeting
of hypoxic portions of residual tumor [5-7]. IORT is
especially helpful in neck disease as a boost for adjuvant
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any medium, provided the original work is properly cited.EBRT. Cons include the theoretical induction of fibrosis
of late responding tissues, the need for additional man-
power in the operating room, and the extension of the
operative time by approximately 45 minutes.
The current study updates our previously reported
experience with management of advanced cervical
metastasis using IORT and neck dissection [8,9]. This
analysis includes evaluation of clinical outcomes of inte-
grating IORT in treatment of advanced cervical metasta-
sis with analysis of potential prognostic factors.
Materials and methods
Study population
Between August 1982 and July 2007, 231 patients were
treated with surgery and IORT for advanced cervical
node metastases from head and neck cancers as part of
initial treatment or for recurrent disease. This was a
very small subset of the general population undergoing
neck surgery as part of the treatment of head and neck
malignancies. Patient demographics are summarized in
table 1. Sixty-one (26.4%) were females and 170 (73.6%)
were males. The median age of the patient population at
the time of primary or salvage surgery with IORT was
63.5 years (range 32.9 to 90.3 yrs). All of these cases
presented with extensive neck disease that had high
chance for lymphovascular or perineural spread, extra-
capsular extension, or extension to surrounding the
deep neck musculature, prevertebral fascia, carotid
artery, or other vital structures that in the opinion of
the treating surgeon might preclude definitive surgical
removal with negative margins and no residual micro-
scopic disease. Simple invasion of resectable muscles
such as the sternocleidomastoid muscle, cranial nerves
XI or XII, the internal jugular vein, etc. were not criteria
for IORT treatment by themselves; such structures were
resected using standard surgical principles and IORT
would not necessarily have been offered.
General indications for treatment included: 1) tumor
that could not be dissected with obviously clean margins
from vital nerves, muscles, the carotid artery, or bony
structures 2) disease which was thought to be more
aggressive than usual, 3) large or bulky disease or N3
nodes, 4) suspected close or positive margins or cases
with suspected residual microscopic disease and 5) prior
full course external beam radiotherapy. If the neck dis-
ease could be removed without significant risk of resi-
dual microscopic or gross disease, IORT was not
considered. The study was performed in accordance
with the Declaration of Helsinki and approved as a ret-
rospective review by the Institutional Review Board at
Methodist Hospital of Indiana. Characteristics of the
study population are summarized in Table 1.
Treatment Methods
All patients were treated by members of a single surgical
practice and a single radiation oncology group. Com-
puted tomography (CT) scanning of the head and neck
was performed on all patients and the images were
reviewed preoperatively by the treating physicians. The
majority of the patients had previously undergone treat-
ment to the neck with either surgery, radiation, or both.
Surgery with IORT was performed for salvage in 198
patients and 26 patients had not been treated previously.
One patient received 10 Gy, two received 12 Gy, 1
received 13 Gy, 83 received 15 Gy, 1 received 17 Gy, 1
received 17.5 Gy, 3 received 18 Gy, 132 received 20 Gy,
and 5 received 25 Gy, all prescribed to the maximum
isodose line. Although the ideal IORT dose is yet to be
determined, prior experience indicates higher incidence
of complications with IORT doses above 20 Gy in HNC
pts (24). Considerations for dose selection in our study
included tumor size, location and prior treatment.
The neck dissections were performed via standard sur-
gical principles. After the resection was completed, the
radiation oncologist entered the operating room to assist
with the IORT portion of the procedure.
There was no single dose, cone size, or electron
energy used for all treatments. Median treatment cone
size was 6.4 cm, ranging from 3 cm to 10.2 cm. As for
beam energy 65 (29.8%),112 (50.5%), and 45 patients
(20.3%) were prescribed 4, 5, and 6 MeV electrons
respectively, dosed to Dmax. There were 88 patients
(39.1%) who received 15 Gy or less and 142 (60.9%)
patients who received more than 15 Gy.
Postoperative EBRT was prescribed to 50 patients at
the discretion of the attending radiation oncologist.
Median dose was 45 Gy (range, 20-66 Gy). Overall, 99
patients received chemotherapy (adjuvant, palliative,
neoadjuvant, etc.). Follow-up consisted of clinical exami-
nations with radiographic follow-up as clinically
indicated.
Statistical analyses
The endpoints analyzed were overall survival (OS),
recurrence-free survival (RFS), and local control (LC).
All events were measured from the date of primary or
Table 1 Patient Characteristics
Characteristic N (%)
Gender
Male 170 (73.6%)
Female 61 (26.4%)
Prior Chemo (yes) 99 (50.5%)
Prior RT (yes) 175 (81.4%)
Surgery Type
Primary 26 (11.6%)
Salvage 198 (88.4%)
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defined as evidence of recurrent disease in the IORT
field. Failures outside the IORT field but within or adja-
cent to the surgical bed were considered regional. One-,
3-, and 5-year estimates of OS and RFS were derived
using the Kaplan-Meier method, with comparisons
among groups performed with 2-sided log-rank tests. A
Cox proportional hazards model was used to identify
characteristics predictive of survival and disease recur-
rence. All tests were two-tailed comparisons, and the
acceptable probability of a type I error was set as less
than 0.05 for statistical significance.
Results
Tumor characteristics
Tumor characteristics are summarized in Table 2. Med-
ian neck tumor size was 4.3 cm. The majority of the
tumors (90.9%) were squamous cell carcinoma (SCC)
arising in the upper aerodigestive tract. Nearly half of
the neck lesions were on right side (n = 114, 49.4%),
39.4% were left-sided (n = 91) 9.1% (n = 21) were bilat-
eral and 2.2% (n = 5) presented in the anterior midline.
Surgical margins of the neck disease were grossly or
microscopically positive p e rf r o z e ns e c t i o ni n4 1p t s
(23.0%), close (generally defined as tumor within 1 mm
to the margin) in 8 pts (4.5%) and histologically negative
per frozen section in 129 pts (72.5%). Lymphovascular
invasion (LVI) and perineural invasion were observed in
29 pts (16.3%) and 30 pts (16.9%), respectively. Extra-
capsular extension (ECE) and dermal invasion were
noted in 22 (12.3%) and 37 pts (20.7%) respectively.
Carotid artery involvement was noted in 60 pts (32.6%).
Overall Survival
With a median follow up of 1.03 yrs (range 0.01 to
21.85 yrs), 53 patients were known to be alive at the
time of this analysis. The 1-, 3- and 5- year survival
rates (Figure 1) were 58%, 34%, and 26%, respectively.
Table 3 shows that patients with carotid involvement
had significantly worse survival with a median survival
of 1 year compared to 2.2 years for patients with unin-
volved carotids (p = 0.01). Pathological features such as
perineural and dermal invasion were also predictive of
decreased survival (p < 0.001 and p = 0.035 respec-
tively). Survival outcomes were not significantly altered
by margin status, dose delivered (< 15 Gy or > 15 Gy),
beam energy (4, 5 or 6 MeV), prior chemotherapy, or
prior RT treatment.
Local control, recurrence, and recurrence-free survival
Recurrence-free survival (RFS) is shown in Figure 2. RFS
at 1, 3, and 5 years was 66%, 55%, and 49%, respectively.
A significantly shorter time to recurrence was noted in
patients who had prior chemotherapy as compared to
chemotherapy naïve patients (1.2 vs. 10.4 years p =
0.045), which was thought to be reflective of the extent
of disease at initial presentation rather than due to the
chemotherapy itself, though this is unproven. Patients
treated with doses above 15 Gy had significantly
improved overall RFS (p = 0.029), but as noted above,
no improvement in OS was noted with dose level. None
of the other studied factors including margin status,
prior RT, postoperative RT, carotid involvement, dermal
invasion, perineural or vascular invasion significantly
impacted RFS.
Thirty eight patients (16%) experienced regional recur-
rence and twenty patients (9%) had local recurrence.
Distant metastases were later detected in twenty five
patients (11%). Fifty seven patients (25%) failed within
t h es u r g i c a lf i e l d .O ft h o s e ,o n l yt w e n t yp a t i e n t s( 9 % )
failed within the IORT field.
Complications
There were no perioperative fatalities. Complications
data was available on 203 pts. Postoperative complica-
tions occurred in 54 pts resulting in 80 complication
events. As shown in Table 4, there were 23 vascular
complications. Among those, there were 10 strokes and
6 hematomas. Other vascular complications included
TIA, carotid blow out, and cardiac ischemic events.
There were 20 pharyngocutaneous fistulas developed
within the first few weeks of surgery and 20 postopera-
tive wound dehiscence events. Sensory neuropathy
developed in 7 cases, 8 pts developed radiation
Table 2 Tumor Characteristics
Characteristic N (%)
Tumor margins
Close Margin 8 (3.4%)
Negative Margin 129 (55.6%)
Positive Margin 41 (17.7%)
Margins Unknown 54 (23%)
Histology
Squamous Cell Carcinoma 210 (90.9%)
Other 21 (9.1%)
Side of Neck for IORT
Anterior 5 (2.2%)
Right 114 (49.4%)
Left 91 (39.4%)
Bilateral 21 (9.1%)
Perineural spread 30 (16.9%)
Lymphovascular involvement 29 (16.3%)
Extracapsular extension 22 (12.3%)
Vascular Invasion 27 (15.1%)
Dermal Invasion 37 (20.7%)
Carotid Involvement 60 (32.6%)
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a reconstructive flap. Mean IORT dose in pts with no
complications was 18.18 Gy vs. 17.77 Gy in pts with at
least one complication. We found no significant correla-
tion between IORT dose delivered and complication risk
(p = 0.361).
Discussion
Advanced cervical metastasis presents significant chal-
lenges to both the head and neck surgeon and the radia-
tion oncologist. Despite advances in surgical and
radiation techniques, survival rates in for patients with
advanced cervical metastasis remains low.
From a radiobiology standpoint, IORT allows delivery
of a high dose of electron beam energy directly to the
region of greatest risk. A single IORT dose is biologi-
cally equivalent to two to three times the same dose
delivered via EBRT [5]. In addition, the proximity of
IORT to the time of resection may be advantageous;
Ang et al. reported improved survival and locoregional
control when patients with advanced head and neck
cancer received radiation within 11 weeks postopera-
tively [10].
The use of IORT for head and neck cancer has been
limited to a handful of institutions. Recently, Chen et al
reported the UCSF experience with 137 pts treated for
recurrent head and neck cancer. Their 3-year in-field
control rate and overall survival rate were 67% and 36%,
respectively [11]. In another study, Pinheiro and collea-
gues reported their results for 44 patients treated at
Mayo clinic. Overall survival and disease free survival
were 32% and 21% for pts with SCC and 50% and 40%
for pts treated for other histologies [12]. Lastly, a retro-
spective study of 38 patients treated at Ohio State with
IORT for recurrent head and neck cancer found that
neck IORT was accompanied by improved overall survi-
val [13]. In our retrospective series, the OS and RFS
were 26% and 49% respectively at 5 years. While our
numbers compare favorably to the literature, one has to
keep in mind the probable inherent heterogeneity of the
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Figure 1 Kaplan-Meier estimates showing overall survival rates for patients undergoing cervical IORT.
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summarized in Table 3 our inclusion criteria for this
study was advanced neck disease that in many institu-
tions would have been deemed poorly resectable or even
unresectable, with nearly a third of the patients present-
ing with frank carotid involvement, 20.7% of the patients
with dermal/skin involvement, and nearly half with
extracapsular spread, Lymphovascular involvement, and/
or perineural spread. The results from this study must
be looked at with this in mind. The majority of these
patients were at high risk for the development of distant
metastatic disease and for failure at the primary upper
aerodigestive site, as well as in the neck.
One major limitation of this study is its retrospective
nature, which by definition limits data availability and
analysis. Furthermore, it is difficult to sort out the bene-
fit attributable to IORT in this population because some
patients received a variety of adjuvant and neoadjuvant
chemotherapy and radiation therapy courses in addition
to neck dissection with IORT.
In a prior study we identified gross residual disease as
a predictor of poor patient outcome after IORT [9]. In
the current report, patients with carotid involvement
had a dismal median OS of 1 year. This reflects the pre-
viously reported high complication rates of 50% in these
patients [8]. This subset of patients is at high risk for
post-treatment cerebrovascular events and neurologic
sequelae.
Several studies have confirmed better disease control
when IORT is used in conjunction with EBRT. Nag et al
reported 79% local control in pts who received addi-
t i o n a lE B R Tv s .5 0 %f o rt h o s ew h oh a dI O R Ta l o n e
[14,15]. In the current series there were 50 pts (24%)
who received post treatment RT. However, there was no
statistically significant difference noted for OS and RFS
for those pts. Perhaps this can be explained by the rela-
tively high number of pts who had prior RT (175 pts) in
this group.
Postoperative complications occurred in 54 pts (27%.)
The majority of these complications were not thought
to be due to the IORT itself, however, but were thought
instead to be reflective of the scope of the surgery in
general for these patients with advanced disease, many
with cancer recurrent or persistent after prior surgery,
RT, and chemotherapy. The majority of the patients, (n
= 175) had undergone previous RT and 50 were given
postoperative RT, so some patients were re-irradiated.
In addition, 99 patients had previously been treated with
chemotherapy. The surgical complication rate in such a
population is high in general [8,16], regardless of
w h e t h e rI O R Ti so f f e r e do rn o t .T h i sp o p u l a t i o ni sa t
high risk for wound dehiscence and postoperative phar-
yngocutaneous fistula formation, and the 20 cases we
experienced in each category were not thought to be a
result of the IORT. In each case, the skin that dehisced
had been shielded with lead and was not exposed to the
radiotherapy beam. Likewise, the pharyngeal mucosa at
the postoperative fistula sites had been appropriately
shielded with lead. Similarly, the partial flap necrosis in
2 of the pts was in non-irradiated tissue which should
not have been affected by the IORT.
Bearing in mind the number of patients with unfavor-
able features included in the study (Table 2), our com-
plication rate of only 27% is acceptable. Reported
Table 3 Statistical correlation of disease characteristics
with survival outcomes
Characteristic (%) Median OS
(y)
p Median RFS
(y)
p
IORT dose 0.863 0.029
≤ 1500 cGy (39.1%) 1.2 1.5
> 1500 cGy (60.9%) 1.5 NE
Energy 0.064 0.006
4 MeV (29%) 1.0 NE
5 MeV (51%) 1.6 NE
6+ MeV (20%) 1.0 0.8
ECE 0.569 0.310
Yes (12%) 1.4 0.9
No (88%) 1.7 3.9
LVI/AVI 0.071 0.064
Yes (16%) 0.8 0.7
No (84%) 1.7 3.9
PNI <
0.001
0.387
Yes (17%) 0.6 1.1
No (83%) 1.9 3.9
Dermal Invasion 0.035 0.911
Yes (21%) 0.9 NE
No (79%) 1.9 3.1
Carotid
Involvement
0.010 0.199
Yes (33%) 1.0 1.1
No (67%) 2.2 NE
Vasc. Complications 0.823 0.894
Yes (11%) 1.2 1.1
No (89%) 1.2 1.5
Prior RT 0.263 0.246
Yes (81%) 1.4 3.2
No (19%) 2.2 NE
Previous Chemo 0.419 0.045
Yes (51%) 1.6 1.2
No (49%) 0.9 10.4
Post Surgery RT 0.457 0.127
No (76%) 1.5 10.4
Yes (24%) 1.6 1.2
Survival times estimated using Kaplan-Meier method and tested between
groups using the long-rank test.
NE - not estimable
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tions ranging from 6.5% to 28.4% (6, 7, 24-26). Such
complications are likely multifactorial in etiology includ-
ing tumor invasion of critical structures and prior treat-
ments in addition to the treatment delivered. Although
the ideal IORT dose is yet to be determined, prior
experience indicates higher incidence of complications
with IORT doses above 20 Gy in HNC pts (24). In addi-
tion to dose other factors that need to be considered
inorder to minimize complications include: cone size,
proper shielding and patient comorbidities. The current
series is the largest reported to date which addresses the
role of IORT in advanced cervical disease. The reported
5 year OS of 26% and RFS of 49% compare favorably to
historical controls. Future efforts should be directed to
improve disease control by decreasing regional and dis-
tant failures. The current study also identifies clinical
factors that correlate with better outcomes. Such prog-
nostic factors are important for refining patient selection
for IORT in the future. Our retrospective analysis sup-
ports incorporation of IORT into future randomized
phase III clinical trials to improve outcomes in patients
with advanced cervical metastasis
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Figure 2 Kaplan-Meier estimates showing recurrence free survival rates for patients undergoing cervical IORT.
Table 4 Complications
Complications
(203 pts with available data)
N (%)
Vascular Complications 23
Radiation osteonecrosis 8
Fistulas 20
Flap Necrosis 2
Wound dehiscence 20
Neuropathy 7
Total events 80
Pts with > 1 complication 54 (27%)
Pts with no complications 149 (73%)
Zeidan et al. Radiation Oncology 2011, 6:72
http://www.ro-journal.com/content/6/1/72
Page 6 of 7Author details
1Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
2Department of Radiation Oncology, Methodist Hospital, Indianapolis, IN,
USA.
3Center for Ear Nose Throat & Allergy, Indianapolis, IN, USA.
4Methodist
Research Institute, Methodist Hospital, Indianapolis, IN, USA.
Authors’ contributions
YHZ analyzed the data and wrote the manuscript. He is the corresponding
author. AY reviewed the manuscript and the data analysis. CT participated in
statistical analysis. DW, SF, EK and RB contributed to discussion and data
analysis. TH participated in data analysis and manuscript writing. All the
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 January 2011 Accepted: 15 June 2011
Published: 15 June 2011
References
1. Mendenhall WM, Million RR, Cassisi NJ: Elective neck irradiation in
squamous-cell carcinoma of the head and neck. Head Neck Surg 1980,
3:15-20.
2. Mendenhall WM, Million RR: Elective neck irradiation for squamous cell
carcinoma of the head and neck: analysis of time-dose factors and
causes of failure. Int J Radiat Oncol Biol Phys 1986, 12:741-746.
3. Freeman SB, Hamaker RC, Singer MI, Pugh N, Garrett P, Ross D:
Intraoperative radiotherapy of skull base cancer. Laryngoscope 1991,
101:507-509.
4. Freeman SB, Hamaker RC, Singer MI, Pugh N, Garrett P, Ross D:
Intraoperative radiotherapy of head and neck cancer. Arch Otolaryngol
Head Neck Surg 1990, 116:165-168.
5. Willett CG, Czito BG, Tyler DS: Intraoperative radiation therapy. J Clin Oncol
2007, 25:971-977.
6. Calvo FA, Meirino RM, Orecchia R: intraoperative radiation therapy part 2.
Clinical results. Crit Rev Oncol Hematol 2006, 59:116-127.
7. Calvo FA, Meirino RM, Orecchia R: Intraoperative radiation therapy first
part: rationale and techniques. Crit Rev Oncol Hematol 2006, 59:106-115.
8. Freeman SB, Hamaker RC, Borrowdale RB, Huntley TC: Management of
neck metastasis with carotid artery involvement. Laryngoscope 2004,
114:20-24.
9. Freeman SB, Hamaker RC, Rate WR, Garrett PG, Pugh N, Huntley TC,
Borrowdale R: Management of advanced cervical metastasis using
intraoperative radiotherapy. Laryngoscope 1995, 105:575-578.
10. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF,
Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and
survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35.
11. Chen AM, Bucci MK, Singer MI, Garcia J, Kaplan MJ, Chan AS, Phillips TL:
Intraoperative radiation therapy for recurrent head-and-neck cancer: the
UCSF experience. Int J Radiat Oncol Biol Phys 2007, 67:122-129.
12. Pinheiro AD, Foote RL, McCaffrey TV, Kasperbauer JL, Bonner JA, Olsen KD,
Cha SS, Sargent DJ: Intraoperative radiotherapy for head and neck and
skull base cancer. Head Neck 2003, 25:217-225; discussion 225-216.
13. Nag S, Schuller DE, Martinez-Monge R, Rodriguez-Villalba S, Grecula J,
Bauer C: Intraoperative electron beam radiotherapy for previously
irradiated advanced head and neck malignancies. Int J Radiat Oncol Biol
Phys 1998, 42:1085-1089.
14. Nag S, Schuller D, Pak V, Grecula J, Bauer C, Young D: IORT using electron
beam or HDR brachytherapy for previously unirradiated head and neck
cancers. Front Radiat Ther Oncol 1997, 31:112-116.
15. Nag S, Schuller D, Pak V, Young D, Grecula J, Bauer C, Samsami N: Pilot
study of intraoperative high dose rate brachytherapy for head and neck
cancer. Radiother Oncol 1996, 41:125-130.
16. Freeman SB: Advanced cervical metastasis involving the carotid artery.
Curr Opin Otolaryngol Head Neck Surg 2005, 13:107-111.
doi:10.1186/1748-717X-6-72
Cite this article as: Zeidan et al.: Intraoperative radiation therapy for
advanced cervical metastasis: a single institution experience. Radiation
Oncology 2011 6:72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zeidan et al. Radiation Oncology 2011, 6:72
http://www.ro-journal.com/content/6/1/72
Page 7 of 7